Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 19;59(1):617–626. doi: 10.1080/13880209.2021.1923759

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — Lappaol F (LAF) downregulated the expression of YAP and its target genes in diverse cancer cell lines. The cells were exposed to LAF at different concentrations for 48 h (left side) or at 50 µmol/L LAF for different durations (right side). VP, a known YAP inhibitor, was added (1 µmol/L) as a positive control. Protein levels were determined by western blotting. (A) HeLa cells. (B) MDA-MB-231 cells. (C) SW480 cells. (D) PC3 cells. All data are expressed as the mean ± SD (n = 3). *p < 0.05, **p < 0.01, significantly different from the control without LAF treatment at the corresponding time points. Bcl-2: B cell lymphoma/leukemia-2; BIRC5: survivin/baculoviral IAP repeat containing 5; c-Myc: cellular myelocytomatosis oncogene; VP: verteporfin; YAP: Yes-associated protein; VP + LAF: LAF (50 µmol/L) combined with VP (1 µmol/L).